Cost-Effectiveness of Apixaban In Prevention of Stroke And Systemic Embolism In The Czech Republic

Apixaban is an oral anticoagulant, direct factor Xa inhibitor. The aim of the analysis was to compare costs and effectiveness of apixaban in the first line prevention of stroke and systemic embolism in vitamin K antagonist (VKA) suitable patients with atrial fibrillation. The analysis was conducted from the perspective of the public healthcare payer in the Czech Republic.

Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: M Kolek, T Spousta, M Karbusicka, P Vothova, P Mazan, J Duba Source Type: research